Dosimetry, biodistribution, and safety of flurpiridaz F 18 in healthy subjects undergoing rest and exercise or pharmacological stress PET myocardial perfusion imaging.
The objectives of this study were to evaluate radiation dosimetry, biodistribution, human safety, and tolerability of 18F-labeled flurpiridaz (Flurpiridaz) in normal subjects undergoing rest and separate-day exercise or adenosine pharmacological stress PET imaging.Methods: 12 normal subjects were in...
| Published in: | Journal of Nuclear Cardiology Vol. 26; no. 6; pp. 2018 - 2031 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | research tables/charts Journal Article |
| Published: |
Elsevier B.V.
Dec2019
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=140312935&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 140312935 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 10713581 1YCL jtl: Journal of Nuclear Cardiology issn: 10713581 maglogo: N pubinfo: dt: Dec2019 vid: 26 iid: 6 pid: 467 pub: Elsevier B.V. place: New York, New York artinfo: ui: 140312935 140312935 144045240 NLM30488323 140312935 10.1007/s12350-018-01484-z NLM30488323 140312935 ppf: 2018 ppct: 13 formats: tig: atl: Dosimetry, biodistribution, and safety of flurpiridaz F 18 in healthy subjects undergoing rest and exercise or pharmacological stress PET myocardial perfusion imaging. aug: au: Maddahi, Jamshid Bengel, Frank Czernin, Johannes Crane, Paul Dahlbom, Magnus Schelbert, Heinrich Sparks, Richard Phelps, Michael Lazewatsky, Joel affil: Department of Molecular and Medical Pharmacology (Nuclear Medicine), David Geffen School of Medicine at University of California, Los Angeles (UCLA), 100 UCLA Medical Plaza Suite 410, 90095-7064, Los Angeles, CA, USA sug: subj: Exercise Radiometry Methods Tomography, Emission-Computed Heterocyclic Compounds Pharmacokinetics Adenosine Pharmacodynamics Adult Heart Function Tests Male Diagnostic Imaging Radiopharmaceuticals Pharmacokinetics Human Patient Safety Female Research Subjects Exercise Test Young Adult Validation Studies Comparative Studies Evaluation Research Multicenter Studies Scales Adult: 19-44 years Male Female ab: The objectives of this study were to evaluate radiation dosimetry, biodistribution, human safety, and tolerability of 18F-labeled flurpiridaz (Flurpiridaz) in normal subjects undergoing rest and separate-day exercise or adenosine pharmacological stress PET imaging.Methods: 12 normal subjects were injected with 58.5 to 121 MBq (1.58 to 3.27 mCi) of Flurpiridaz intravenously at rest on Day 1 and 57 to 171 MBq (1.54 to 4.61 mCi) during stress on Day 2. Sequential whole-body imaging was performed for 5 hours. Blood samples were collected for up to 8 hours.Results: The heart wall received the largest mean absorbed dose with both exercise and adenosine stresses. The mean effective dose was 0.054 rem/mCi (0.015 mSv/MBq) with exercise and 0.069 rem/mCi (0.019 mSv/MBq) with adenosine pharmacological stress. The maximum dose that may be administered without exceeding 1 rem (10 mSv) effective dose was 19 mCi (685 MBq) for exercise and 15 mCi (539 MBq) for adenosine pharmacological stress. There were no drug-related adverse events, and the tracer was well tolerated in all subjects.Conclusion: Based on radiation dosimetry, biodistribution, and safety observations, 18F-labeled flurpiridaz is found suitable for clinical PET myocardial perfusion imaging in conjunction with either exercise or pharmacological stress testing. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|